Quince Therapeutics ( (QNCX) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quince Therapeutics, Inc. has notified regulators that it will delay filing its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025, via a Form 12b-25. The late filing concerns the company’s Annual Report on Form 10-K (Yearly Report), which is ordinarily due shortly after year-end for U.S. listed issuers.
The company attributes the delay to the need for additional time to complete accounting procedures and required disclosures following recent internal disruptions. These stem from workforce reductions and the fallout from negative top-line data in its pivotal Phase 3 clinical trial, which failed to meet its primary endpoint.
In response to the failed Phase 3 study, Quince implemented cash-preservation measures, including staff cuts, while it evaluates strategic options for the business. Management notes that the combination of reduced headcount and added accounting and strategic complexity has slowed its normal financial close and reporting processes.
Quince states that it expects to file the delayed Form 10-K (Yearly Report) within the standard 15-day extension window allowed under SEC Rule 12b-25. Investors should therefore anticipate the Annual Report to be submitted no later than fifteen calendar days after the original deadline, barring unforeseen issues.
The company does not anticipate any significant change in results of operations compared with the prior fiscal year based on what will be reflected in the upcoming earnings statements. While no preliminary financial figures are provided, the notification implies that headline financial trends should be broadly consistent, subject to usual forward-looking uncertainties.
Quince affirms that all other required periodic filings over the past 12 months have been submitted on time, signaling continued regulatory compliance apart from this delay. The notification is signed on behalf of the company by Brendan Hannah, Chief Business Officer, Chief Operating Officer, and Chief Compliance Officer, underscoring management’s accountability for completing the Form 10-K (Yearly Report) as soon as practicable.
The most recent analyst rating on (QNCX) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.
The score is driven primarily by very weak financial performance (no revenue, large losses, sustained cash burn, and a significantly weakened equity position with higher leverage). Technicals also weigh on the score due to a strong downtrend, while valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Average Trading Volume: 68,875,556
Technical Sentiment Signal: Sell
Current Market Cap: $5.65M
Learn more about QNCX stock on TipRanks’ Stock Analysis page.